International reimbursement policies on drugs for pulmonary arterial hypertension and enlightenment to China
- Author:
Yi-Ru GUAN
1
Author Information
- Publication Type:Journal Article
- Keywords: Medical insurance; Orphan drug; Pulmonary arterial hypertension; Rare disease; Reimbursement policy; Targeted therapy
- From: Chinese Pharmaceutical Journal 2015;50(18):1639-1642
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To introduce international reimbursement policies on drugs for pulmonary arterial hypertension (PAH), and provide a reference for establishing relevant policies in China. METHODS: Reimbursement policies on PAH drugs of Australia, Canada, America and some EU countries were analyzed and compared with the status quo in China. RESULTS: Although expensive, PAH drugs are reimbursed by medical insurance in most countries included in this study. However, the accessibility of PAH drugs in China remains very poor with only a few cities including these drugs in the medical insurance. Patients with PAH face with poverty caused by disease, even abandoning treatment. CONCLUSION: Learning the experience from countries with rare disease act and good medical insurance system and analysing the earliest attempts to reimburse PAH drugs in China will help promote the reimbursement policy on PAH drugs in China.
